EMEA-002318-PIP03-19

Key facts

Active substance
tilsotolimod
Therapeutic area
Oncology
Decision number
P/0222/2019
PIP number
EMEA-002318-PIP03-19
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of malignant melanoma
Route(s) of administration
Intratumoral use
Contact for public enquiries
Idera Pharmaceuticals Inc.

Tel.: +1 4843481600
E-mail: info@iderpharma.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating